Boothbay Fund Management’s Avidity Biosciences RNAM Stock Holding History

Boothbay Fund Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,582	Closed	-$4.37M	–	2422
2025 Q4	$4.37M	Buy	60,582 +7,895	+15%	+$510K	0.07%	330
2025 Q3	$2.3M	Buy	52,687 +42,687	+427%	+$1.73M	0.03%	535
2025 Q2	$284K	Buy	+10,000	New	+$298K	0.01%	1126

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Boothbay Fund Management's RNAM Position: Q1 2026 in Review

Boothbay Fund Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 60,582 shares — an estimated $4.37M sold.

Boothbay Fund Management first reported a position in RNAM in Q2 2025 and held it in 3 quarters. The position peaked at $4.37M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Boothbay Fund Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Boothbay Fund Management sold 60,582 Avidity Biosciences shares in Q1 2026, an estimated $4.37M.
Boothbay Fund Management first reported a position in Avidity Biosciences in Q2 2025 and held it in 3 quarters.
Boothbay Fund Management's Avidity Biosciences position peaked at $4.37M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.